327 related articles for article (PubMed ID: 33346435)
21. Riociguat: Clinical research and evolving role in therapy.
Klinger JR; Chakinala MM; Langleben D; Rosenkranz S; Sitbon O
Br J Clin Pharmacol; 2021 Jul; 87(7):2645-2662. PubMed ID: 33242341
[TBL] [Abstract][Full Text] [Related]
22. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
23. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
24. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry.
Ghofrani HA; Gomez Sanchez MA; Humbert M; Pittrow D; Simonneau G; Gall H; Grünig E; Klose H; Halank M; Langleben D; Snijder RJ; Escribano Subias P; Mielniczuk LM; Lange TJ; Vachiéry JL; Wirtz H; Helmersen DS; Tsangaris I; Barberá JA; Pepke-Zaba J; Boonstra A; Rosenkranz S; Ulrich S; Steringer-Mascherbauer R; Delcroix M; Jansa P; Šimková I; Giannakoulas G; Klotsche J; Williams E; Meier C; Hoeper MM;
Respir Med; 2021 Mar; 178():106220. PubMed ID: 33540340
[TBL] [Abstract][Full Text] [Related]
25. Guanylate cyclase stimulators for pulmonary hypertension.
Wardle AJ; Seager MJ; Wardle R; Tulloh RM; Gibbs JS
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD011205. PubMed ID: 27482837
[TBL] [Abstract][Full Text] [Related]
26. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
DeSouza SA; Preston IR
Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
[TBL] [Abstract][Full Text] [Related]
27. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study.
Halank M; Hoeper MM; Ghofrani HA; Meyer FJ; Stähler G; Behr J; Ewert R; Fletcher M; Colorado P; Nikkho S; Grimminger F
Respir Med; 2017 Jul; 128():50-56. PubMed ID: 28610669
[TBL] [Abstract][Full Text] [Related]
28. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
Binder C; Zotter-Tufaro C; Bonderman D
Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
[TBL] [Abstract][Full Text] [Related]
29. Riociguat: first global approval.
Conole D; Scott LJ
Drugs; 2013 Nov; 73(17):1967-75. PubMed ID: 24218053
[TBL] [Abstract][Full Text] [Related]
30. Riociguat for patients with chronic thromboembolic pulmonary hypertension: Usefulness of transitioning from phosphodiesterase type 5 inhibitor.
Yamamoto K; Tanabe N; Suda R; Sasaki A; Matsumura A; Ema R; Kasai H; Kato F; Sekine A; Nishimura R; Jujo T; Sugiura T; Shigeta A; Sakao S; Tatsumi K
Respir Investig; 2017 Jul; 55(4):270-275. PubMed ID: 28705306
[TBL] [Abstract][Full Text] [Related]
31. Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat.
Frey R; Becker C; Saleh S; Unger S; van der Mey D; Mück W
Clin Pharmacokinet; 2018 Jun; 57(6):647-661. PubMed ID: 29086344
[TBL] [Abstract][Full Text] [Related]
32. A focus on riociguat in the treatment of pulmonary arterial hypertension.
Toxvig AK; Wehland M; Grimm D; Infanger M; Krüger M
Basic Clin Pharmacol Toxicol; 2019 Sep; 125(3):202-214. PubMed ID: 31206240
[TBL] [Abstract][Full Text] [Related]
33. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
34. Right ventricular size and function under riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (the RIVER study).
Marra AM; Halank M; Benjamin N; Bossone E; Cittadini A; Eichstaedt CA; Egenlauf B; Harutyunova S; Fischer C; Gall H; Ghofrani HA; Hoeper MM; Lange TJ; Olsson KM; Klose H; Grünig E
Respir Res; 2018 Dec; 19(1):258. PubMed ID: 30567595
[TBL] [Abstract][Full Text] [Related]
35. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
Sandner P; Becker-Pelster EM; Stasch JP
Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
[TBL] [Abstract][Full Text] [Related]
36. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
Sulica R; Fenton R; Cefali F
Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
[TBL] [Abstract][Full Text] [Related]
37. [Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat].
Martynyuk TV; Shmalts AA; Gorbachevsky SV; Chazova IE
Ter Arkh; 2021 Sep; 93(9):1117-1124. PubMed ID: 36286873
[TBL] [Abstract][Full Text] [Related]
38. Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.
Mihalek AD; Scott CD; Mazimba S
Vasc Health Risk Manag; 2022; 18():823-832. PubMed ID: 36299800
[TBL] [Abstract][Full Text] [Related]
39. Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH.
Gall H; Vachiéry JL; Tanabe N; Halank M; Orozco-Levi M; Mielniczuk L; Chang M; Vogtländer K; Grünig E
Lung; 2018 Jun; 196(3):305-312. PubMed ID: 29470642
[TBL] [Abstract][Full Text] [Related]
40. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
Loukanov T; Geiger R; Agrawal R
Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
